StonvexLoading…
StonvexStonvexStonvexCore line items from GENI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $669.49M | $510.89M | $412.98M | $341.03M |
Operating Income | $-151.33M | $-58.54M | $-74.16M | $-182.87M |
Net Income | $-111.58M | $-63.04M | $-85.53M | $-181.64M |
EPS (Diluted) | $-0.44 | $-0.27 | $-0.38 | $-0.85 |
Total Assets | $1.13B | $792.27M | $775.72M | $773.34M |
Total Liabilities | $405.81M | $219.86M | $202.71M | $196.52M |
Cash & Equivalents | $280.56M | $110.21M | $100.33M | $122.72M |
Free Cash Flow OCF − CapEx | $64.54M | $69.57M | $11.31M | $-9.42M |
Shares Outstanding | 254.76M | 229.51M | 225.88M | 198.94M |